Analytical method development and validation of olmutinib bulk drug as per ICH Q2 guidelines by using RP-HPLC Method

Authors

  • BALU KHANDARE Kasturi Shikshan Sanstha College of Pharmacy Shikrapur Pune, Maharashtra,India-412208
  • Atish C. Musle
  • Sanket S. Arole
  • Pravin V. Popalghat

Abstract

RP-HPLC is fast, simple, sensitive, precise, and reproducible (liquid chromatography) method, developed and validated to analyseolmutinib bulk dosage form. Using C-18 HPLC column separation was carried out. This was maintained at ambient temperature. During separation mobile phase consist of methanol (100 v/v) was delivered at a rate of 1mL/min. Using UV detector analysis was carried out at the wavelength 267.68 nm. RP-HPLC method was validated by using various parameters like, precision, limit of quantitation (LOQ), linearity and robustness. The RP-HPLC method was found to be linear over the concentration ranges from 50-100 μg/mL (r2 =0.999). Retention time for bulk olmutinib was found to be 9.349 min. LOQ of method was 5.8540 μg/mL and LOD 3.0536μg/mL. Thus, the developed RP-HPLC method was found to be robust and rugged which can be applied for the regular analysis of olmutinib in the bulk as well as pharmaceutical dosage form.

Keywords: C18, RP-HPLC, Methanol, Olmutinib

DOI

https://doi.org/10.22270/jddt.v9i4-A.3527

Published

2019-08-30
Statistics
Abstract Display: 720
PDF Downloads: 718

How to Cite

1.
KHANDARE B, Musle AC, Arole SS, Popalghat PV. Analytical method development and validation of olmutinib bulk drug as per ICH Q2 guidelines by using RP-HPLC Method. J. Drug Delivery Ther. [Internet]. 2019 Aug. 30 [cited 2026 Feb. 2];9(4-A):608-11. Available from: https://www.jddtonline.info/index.php/jddt/article/view/3527

Issue

Vol. 9 No. 4-A (2019): Volume 9, Issue 4-A, July-Aug 2019 (Supplement Issue-2)

Section

Research

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

How to Cite

1.
KHANDARE B, Musle AC, Arole SS, Popalghat PV. Analytical method development and validation of olmutinib bulk drug as per ICH Q2 guidelines by using RP-HPLC Method. J. Drug Delivery Ther. [Internet]. 2019 Aug. 30 [cited 2026 Feb. 2];9(4-A):608-11. Available from: https://www.jddtonline.info/index.php/jddt/article/view/3527
Crossref
Scopus
Google Scholar
Europe PMC